Evidence map›Paper›PMID 42764263›Full record

ArticleMolecular genetics & genomic medicine2026

Mutation Spectrum and Novel Rare Variants in a Han Chinese Hearing Loss Cohort Using a Tiered Sequencing Strategy.

Yu Zhang, Shimei Yuan, Yafang Wan, Tian Li, Lanlan Xu, Wei Yang, Changchun Niu

Abstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu ZhangDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China.ORCID https://orcid.org/0009-0004-5276-6777
Shimei YuanDepartment of Medical Laboratory, Dianjiang General Hospital of Chongqing, Chongqing, China.
Yafang WanDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China.
Tian LiDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China.
Lanlan XuDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China.
Wei YangDepartment of Medical Laboratory, Dianjiang General Hospital of Chongqing, Chongqing, China.
Changchun NiuDepartment of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China.

Funding

Chongqing special project for technological innovation and application development CSTB2023TIAD-KPX0063General Program of National Natural Science Foundation of China 82673032The Joint project of Chongqing Health Commission and Science and Technology Bureau 2024MSXM105
6 · The paper itself

Abstract

backgroundHereditary hearing loss is a genetically heterogeneous disorder posing challenges for molecular diagnosis. This study aimed to characterize the mutation spectrum, including rare and previously unreported variants, using a tiered strategy in a Han Chinese cohort from Southwest China.

methodsIn this retrospective study, 43 patients underwent targeted hotspot screening, followed by whole-exome sequencing in 11 patients with no hotspot variants detected. Variants were annotated and interpreted according to American College of Medical Genetics and Genomics guidelines.

resultsInitial hotspot screening established molecular diagnoses in 23 patients based on seven pathogenic or likely pathogenic variants in MT-RNR1, GJB2, and SLC26A4. Whole-exome sequencing identified six additional rare variants in CDH23, ILDR1, OTOF, and SLC12A2, and established two diagnoses involving ILDR1 and CDH23. A previously unreported SLC12A2 missense variant, c.2936A>G (p.Glu979Gly) was identified as a variant of uncertain significance and retained as a candidate finding. CDH23 c.5311C>T (p.Arg1771Ter) has not previously been reported in Han Chinese patients with hearing loss, to our knowledge.

conclusionsThese findings expand the mutation spectrum of hereditary hearing loss in a Han Chinese cohort from Southwest China and highlight the practical value of a tiered testing strategy integrating targeted hotspot screening with whole-exome sequencing.

Indexed as

Hearing LossMutationAdolescentAdultCadherin Related ProteinsCadherinsChildChild, PreschoolChinaConnexin 26East Asian PeopleExome SequencingFemaleHumansMaleMembrane ProteinsCadherin Related ProteinsCadherinsCDH23 protein, humanConnexin 26Membrane ProteinsSulfate TransportersHan Chinesemutation spectrumrare variantstiered sequencing strategywhole‐exome sequencing

Identifiers

PMID42764263
PMCPMC13590426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.